Short Communication Vol. 7 No. 2 (2020): European Journal of Rheumatology DOI: https://doi.org/10.5152/eurjrheum.2020.20061 Article Sidebar Full Text PDF Published: Apr 17, 2020 Keywords: AVES Editorial Office Main Article Content Hèctor Corominas Department of Rheumatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain Ivan Castellví Department of Rheumatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain Pere Domingo Infectious Diseases Unit, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain Jordi Casademont Department of Internal Medicine, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain Facing the SARS-CoV-2 (COVID-19) outbreak with IL-6R antagonists Main Article Content Hèctor Corominas Department of Rheumatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain Ivan Castellví Department of Rheumatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain Pere Domingo Infectious Diseases Unit, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain Jordi Casademont Department of Internal Medicine, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain Abstract Cite this article as: Corominas H, Castellví I, Domingo P, Casademont J. Facing the SARS-CoV-2 (COVID-19) outbreak with IL-6R antagonists. Eur J Rheumatol 2020; 7(Suppl 2): S107-9. Article Details
